72 related articles for article (PubMed ID: 22293715)
1. Serum levels of CC chemokine receptor 4 and CXC chemokine receptor 3 ligands in CD8(+) Sézary syndrome.
Uchi H; Hayashida S; Takahara M; Moroi Y; Furue M
Acta Derm Venereol; 2012 May; 92(3):280-1. PubMed ID: 22293715
[No Abstract] [Full Text] [Related]
2. Expression pattern of chemokine receptors and chemokine release in inflammatory erythroderma and Sézary syndrome.
Fierro MT; Comessatti A; Quaglino P; Ortoncelli M; Osella Abate S; Ponti R; Novelli M; Bernengo MG
Dermatology; 2006; 213(4):284-92. PubMed ID: 17135733
[TBL] [Abstract][Full Text] [Related]
3. Serum chemokine levels differentially regulated by vorinostat in a Sézary syndrome patient.
Miyagaki T; Sugaya M; Oka T; Fujita H; Sato S
Br J Dermatol; 2015 Aug; 173(2):620-2. PubMed ID: 25640919
[No Abstract] [Full Text] [Related]
4. Bexarotene blunts malignant T-cell chemotaxis in Sezary syndrome: reduction of chemokine receptor 4-positive lymphocytes and decreased chemotaxis to thymus and activation-regulated chemokine.
Richardson SK; Newton SB; Bach TL; Budgin JB; Benoit BM; Lin JH; Yoon JS; Wysocka M; Abrams CS; Rook AH
Am J Hematol; 2007 Sep; 82(9):792-7. PubMed ID: 17546636
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Sézary syndrome with bexarotene after IFNalpha and methotrexate failure.
Bagot M
Dermatol Clin; 2008 Jan; 26 Suppl 1():27-9. PubMed ID: 18405184
[No Abstract] [Full Text] [Related]
6. Epstein-Barr virus-associated B-cell lymphoproliferative disorder in a patient with Sézary syndrome treated by methotrexate.
Ingen-Housz-Oro S; Ortonne N; Cordel N; Moroch J; Do-Pham G; Delfau MH; Haioun C; Chosidow O
Br J Dermatol; 2016 Aug; 175(2):430-3. PubMed ID: 27031298
[No Abstract] [Full Text] [Related]
7. Association of autoimmunity and long-term complete remission in patients with Sézary syndrome treated with mogamulizumab.
Bonnet P; Battistella M; Roelens M; Ram-Wolff C; Herms F; Frumholtz L; Bouaziz JD; Brice P; Moins-Teisserenc H; Bagot M; de Masson A
Br J Dermatol; 2019 Feb; 180(2):419-420. PubMed ID: 30328116
[No Abstract] [Full Text] [Related]
8. Disappearance of seborrheic keratoses following treatment with methotrexate.
Seyfer SJ; Duvic M
Cutis; 2013 Jul; 92(1):E2-3. PubMed ID: 23961531
[No Abstract] [Full Text] [Related]
9. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome.
Ishida T; Utsunomiya A; Iida S; Inagaki H; Takatsuka Y; Kusumoto S; Takeuchi G; Shimizu S; Ito M; Komatsu H; Wakita A; Eimoto T; Matsushima K; Ueda R
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3625-34. PubMed ID: 14506150
[TBL] [Abstract][Full Text] [Related]
10. Chemokine receptor expression in cutaneous T cell and NK/T-cell lymphomas: immunohistochemical staining and in vitro chemotactic assay.
Yagi H; Seo N; Ohshima A; Itoh T; Itoh N; Horibe T; Yoshinari Y; Takigawa M; Hashizume H
Am J Surg Pathol; 2006 Sep; 30(9):1111-9. PubMed ID: 16931956
[TBL] [Abstract][Full Text] [Related]
11. Release of both CCR4-active and CXCR3-active chemokines during human allergic pulmonary late-phase reactions.
Bochner BS; Hudson SA; Xiao HQ; Liu MC
J Allergy Clin Immunol; 2003 Nov; 112(5):930-4. PubMed ID: 14610482
[TBL] [Abstract][Full Text] [Related]
12. Circulating clonal CLA(+) and CD4(+) T cells in Sezary syndrome express the skin-homing chemokine receptors CCR4 and CCR10 as well as the lymph node-homing chemokine receptor CCR7.
Sokolowska-Wojdylo M; Wenzel J; Gaffal E; Lenz J; Speuser P; Erdmann S; Abuzahra F; Bowman E; Roszkiewicz J; Bieber T; Tüting T
Br J Dermatol; 2005 Feb; 152(2):258-64. PubMed ID: 15727636
[TBL] [Abstract][Full Text] [Related]
13. Expression of chemokines and chemokine receptors in cutaneous CD30+ lymphoproliferative disorders.
Yamaguchi T; Ohshima K; Karube K; Kawano R; Nakayama J; Suzumiya J; Kikuchi M
Br J Dermatol; 2006 May; 154(5):904-9. PubMed ID: 16634894
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of Sézary syndrome with lymphomatous transformation to large cell lymphoma with fludarabine phosphate.
Nikko AP; RutherFord CJ; Pandya AG
Arch Dermatol; 1996 Aug; 132(8):978-9. PubMed ID: 8712858
[No Abstract] [Full Text] [Related]
15. Can the level of CD52 expression on Sézary cells be used to predict the response of Sézary syndrome to alemtuzumab?
Fernandes IC; Gonçalves M; dos Anjos Teixeira M; Gonçalves C; Coutinho J; Selores M; Alves R; Lima M
J Am Acad Dermatol; 2012 Nov; 67(5):1083-5. PubMed ID: 23062898
[No Abstract] [Full Text] [Related]
16. Lack of apoptosis of Sézary cells in the circulation following oral bexarotene therapy.
Brennand S; Sutton VR; Biagi J; Trapani JA; Westerman D; McCormack CJ; Seymour JF; Kennedy G; Prince HM
Br J Dermatol; 2005 Jun; 152(6):1199-205. PubMed ID: 15948982
[TBL] [Abstract][Full Text] [Related]
17. Production of thymus and activation-regulated chemokine and macrophage-derived chemokine by CCR4+ adult T-cell leukemia cells.
Shimauchi T; Imai S; Hino R; Tokura Y
Clin Cancer Res; 2005 Mar; 11(6):2427-35. PubMed ID: 15788694
[TBL] [Abstract][Full Text] [Related]
18. Oral bexarotene in a therapy-resistant Sézary syndrome patient: observations on Sézary cell compartmentalization.
el-Azhary RA; Bouwhuis SA
Int J Dermatol; 2005 Jan; 44(1):25-8. PubMed ID: 15663654
[TBL] [Abstract][Full Text] [Related]
19. Alemtuzumab in refractory Sézary syndrome.
Reifs CM; Salido-Vallejo R; Garnacho-Saucedo GM; Corte-Sánchez S; González-Menchen A; García-Nieto AV
An Bras Dermatol; 2016; 91(5):642-644. PubMed ID: 27828640
[TBL] [Abstract][Full Text] [Related]
20. CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified.
Ishida T; Inagaki H; Utsunomiya A; Takatsuka Y; Komatsu H; Iida S; Takeuchi G; Eimoto T; Nakamura S; Ueda R
Clin Cancer Res; 2004 Aug; 10(16):5494-500. PubMed ID: 15328188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
